Assessment of the 31-Gene Expression Profile Test by Dermatologists: A Cross-Sectional Survey from National Dermatology Conferences
Main Article Content
Keywords
Melanoma, Pigmented Lesions, 31-Gene Expression Profile, Prognosis, Survey
Abstract
Background: The 31-gene expression profile (31-GEP) test uses 31 genetic markers obtained from the initial biopsy of a melanoma to assess melanoma-specific survival and sentinel lymph node positivity.
Objective: To assess the professional understanding, opinions, and clinical usage of the 31-GEP test by dermatologists.
Methods: Data from 589 unique dermatologists were collected during 2 virtual, nation-wide dermatology conferences via an 18-question survey on practice demographics and their clinical use and opinion of the 31-GEP test.
Results: Participants reported that integrating the 31-GEP test may benefit patients by increasing knowledge and understanding (72.5%), personalizing treatment options (58.8%), and easing uncertainty about the future (59.7%). Benefits of using the 31-GEP test included identifying true negative patients in high-risk populations (65.6%) as well as true positives in low-risk populations (70.6%).A majority of participants also noted that if a patient received a 31-GEP Class 2B result, they would escalate subsequent management even if the lesions were classified as T1 (61.4%) or AJCC8 Stage I (59.0%). 84.9% of participants were somewhat to very likely to use 31-GEP testing for patient management or recommend this test to a colleague.
Limitations: Potential respondent-selection and recall bias.
Conclusion: Dermatologists are increasingly integrating the 31-GEP test into their melanoma clinical management decisions. As the 31-GEP test becomes more prevalent in practice, patients may benefit from decreased anxiety and uncertainty from enhanced prognosis, decreased need for unwarranted procedures such as sentinel lymph node biopsy and optimized allocation of healthcare resources.
References
2. Berman, B., Ceilley, R., Cockerell, C., Ferris, L., High, W. A., Lebwohl, M., Nestor, M. S., Rosen, T., Litchman, G. H., Prado, G., Svoboda, R. M., & Rigel, D. S. (2019). Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Delphi Process Assessment. SKIN The Journal of Cutaneous Medicine, 3(5), 291-306. https://doi.org/10.25251/skin.3.5.1
3. Marks, E., Caruso, H. G., Kurley, S. J., Ibad, S., Plasseraud, K. M., Monzon, F. A., & Cockerell, C. J. (2019). Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma. SKIN The Journal of Cutaneous Medicine, 3(4), 239-249. https://doi.org/10.25251/skin.3.4.2
4. Rigel DS, Ceilley RI, Litchman GH, Cockerell CJ. Gene expression profile testing in skin cancer prognosis: the data is clear – it’s time to get on board. SKIN The Journal of Cutaneous Medicine. 2020;4 (4):304-308. https://jofskin.org/index.php/skin/article/view/937
5. Greenhaw BN, Covington KR, Kurley SJ, Yeniay Y, Cao NA, Plasseraud KM, Cook RW, Hsueh EC, Gastman BR, Wei ML. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. J Am Acad Dermatol. 2020 Sep;83(3):745-753. doi: 10.1016/j.jaad.2020.03.053. Epub 2020 Mar 27. PMID: 32229276.
6. Berman, B., Ceilley, R., Cockerell, C., Ferris, L., High, W. A., Lebwohl, M., Nestor, M. S., Rosen, T., Litchman, G. H., Prado, G., Svoboda, R. M., & Rigel, D. S. (2019). Appropriate Use Criteria for the Integration of Diagnostic and Prognostic Gene Expression Profile Assays into the Management of Cutaneous Malignant Melanoma: An Expert Panel Consensus-Based Modified Delphi Process Assessment. SKIN The Journal of Cutaneous Medicine, 3(5), 291-306. https://doi.org/10.25251/skin.3.5.1
7. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. American family physician 2004;69:548-56.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.